[go: up one dir, main page]

WO2008024027A3 - Use of 9-oxoacridine-10-acetic acid, its salts and esters for enhancing the efficacy of antiandrogenic treatment - Google Patents

Use of 9-oxoacridine-10-acetic acid, its salts and esters for enhancing the efficacy of antiandrogenic treatment Download PDF

Info

Publication number
WO2008024027A3
WO2008024027A3 PCT/RU2007/000424 RU2007000424W WO2008024027A3 WO 2008024027 A3 WO2008024027 A3 WO 2008024027A3 RU 2007000424 W RU2007000424 W RU 2007000424W WO 2008024027 A3 WO2008024027 A3 WO 2008024027A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxoacridine
esters
acetic acid
decrease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2007/000424
Other languages
French (fr)
Other versions
WO2008024027A2 (en
Inventor
Kirill Gennadievich Surkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008024027A2 publication Critical patent/WO2008024027A2/en
Publication of WO2008024027A3 publication Critical patent/WO2008024027A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides the use of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters for the treatment of conditions for which decrease of androgen action is therapeutically favourable. Further, a pharmaceutical composition for decrease of androgen action is provided, comprising (a) 9-oxoacridine-10-acetic acid, its pharmaceutical acceptable salts or esters and (b) at least one antiandrogenic agent, as well as a method of treatment of conditions for which decrease of androgen action is therapeutically favorable, comprising the steps of: (a) administration of an effective amount of a compound selected from the group including 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters to a patient in need of such therapy and (b) hormonotherapy aimed at decrease of androgen action. Such conditions include but not limited to, alopecia, adenoma of prostate, prostate cancer and increased risk of prostate cancer relapse.
PCT/RU2007/000424 2006-07-31 2007-07-31 Use of 9-oxoacridine-10-acetic acid, its salts and esters for enhancing the efficacy of antiandrogenic treatment Ceased WO2008024027A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006127808 2006-07-31
RU2006127808/15A RU2328285C2 (en) 2006-07-31 2006-07-31 Means and method of conditions treatment implying androgen action decrease is considered to be favourable, and method of androgen-dependent tissue sensitivity itensifying using 9-oxoacridine-10-acetic acid

Publications (2)

Publication Number Publication Date
WO2008024027A2 WO2008024027A2 (en) 2008-02-28
WO2008024027A3 true WO2008024027A3 (en) 2008-06-05

Family

ID=39107235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000424 Ceased WO2008024027A2 (en) 2006-07-31 2007-07-31 Use of 9-oxoacridine-10-acetic acid, its salts and esters for enhancing the efficacy of antiandrogenic treatment

Country Status (2)

Country Link
RU (1) RU2328285C2 (en)
WO (1) WO2008024027A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681360A (en) * 1971-04-09 1972-08-01 Hoffmann La Roche Antiviral substituted acridanones
RU2126253C1 (en) * 1996-06-06 1999-02-20 Сурков Кирилл Геннадьевич Agent inducing estrogen and progestine receptors
RU2162843C2 (en) * 1998-05-19 2001-02-10 Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" Method of preparing sodium 10-methylene carboxylate-9-acridone or 10- methylenecarboxy-9-acridone from acridone
UA11926U (en) * 2005-07-11 2006-01-16 Volodymyr Volodymyrovy Kilessa Method for immune correction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010842A1 (en) * 1995-09-19 1997-03-27 Schering Aktiengesellschaft COMBINATION OF β-INTERFERON FOR THE TREATMENT OF PROSTATE CANCER
RU2258503C1 (en) * 2004-01-20 2005-08-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Method for treating prostatic cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681360A (en) * 1971-04-09 1972-08-01 Hoffmann La Roche Antiviral substituted acridanones
RU2126253C1 (en) * 1996-06-06 1999-02-20 Сурков Кирилл Геннадьевич Agent inducing estrogen and progestine receptors
RU2162843C2 (en) * 1998-05-19 2001-02-10 Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" Method of preparing sodium 10-methylene carboxylate-9-acridone or 10- methylenecarboxy-9-acridone from acridone
UA11926U (en) * 2005-07-11 2006-01-16 Volodymyr Volodymyrovy Kilessa Method for immune correction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1996, SURKOV K G ET AL: "[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer]", XP002474585, Database accession no. NLM9123898 *
SZULC B ET AL: "COMPETITION OF SODIUM SALT OF 9-OXO-10-ACRIDINEACETIC ACID WITH ANALOGS DURING INDUCTION OF INTERFERON IN THE MOUSE BONE MARROW-DERIVED MACROPHAGES", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, POLISH ACADEMY OF SCIENCES, WROCLAW, PL, vol. 33, no. 219, 1985, pages 287 - 297, XP009015170, ISSN: 0004-069X *
SZULC Z ET AL: "SYNTHESIS OF CHOLINE ESTER OF 9-OXO-10-ACRIDINEACETIC ACID AND OF CONGENERS AS POTENTIAL INTERFERON INDUCERS", POLISH JOURNAL OF CHEMISTRY, POLISH CHEMICAL SOCIETY, vol. 60, no. 4-6, 1986, pages 615 - 619, XP009015180 *
TSYRLINA YE V ET AL: "Effect of neoadjuvant therapy with neovir on steroid hormone receptor level in endometrial carcinoma", VOPROSY ONKOLOGII (ST. PETERSBURG), vol. 47, no. 2, 2001, pages 214 - 217, XP009097909, ISSN: 0507-3758 *
VOPROSY ONKOLOGII 1996, vol. 42, no. 6, 1996, pages 28 - 32, ISSN: 0507-3758 *

Also Published As

Publication number Publication date
RU2328285C2 (en) 2008-07-10
WO2008024027A2 (en) 2008-02-28
RU2006127808A (en) 2008-02-10

Similar Documents

Publication Publication Date Title
WO2009076170A3 (en) Combinations of therapeutic agents for treating cancer
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
WO2008070041A3 (en) Inhibitors of akt activity
EP2620432A3 (en) Diarylhydantoin compounds
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
WO2011047439A8 (en) Novel parasite therapy
WO2009129147A3 (en) Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2007097989A3 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2009114658A3 (en) Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2008072952A3 (en) Anti-inflammatory compounds containing compositions for treatment of cancer
WO2008125800A3 (en) Mmp activated vascular disrupting agents
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
WO2008024026A3 (en) Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer
WO2010005585A3 (en) 4-aminoquinazoline prodrugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07808752

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07808752

Country of ref document: EP

Kind code of ref document: A2